Carcinoma of Unknown Primary — Trials

Carcinoma of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,156
Recruiting: 2,259
Ph III recruiting: 269
Growth YoY: +12.3%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,893)

clinicaltrialsPublishedShowing 601–650 of 6,216 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05713838	Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery	active not recruiting	Phase 2	32	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER	1	Aug 7, 2026	clinicaltrials
NCT06515990	A Study of DM005 in Patients With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	208	Doma Biopharmaceutical（Suzhou）Co., Ltd.INDUSTRY